Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bispecific fusion protein having therapeutic and diagnostic potential

A fusion protein, bispecific technology, applied in the field of treatment of acute or chronic vascular diseases, can solve problems such as danger

Inactive Publication Date: 2010-02-10
UNIV TUBINGEN
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Because currently used stents are coated with a drug that is gradually released after implantation, reendothelialization of the treated vessel is also delayed by the released drug, and stent thrombosis is an extremely dangerous complication of this approach

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific fusion protein having therapeutic and diagnostic potential
  • Bispecific fusion protein having therapeutic and diagnostic potential
  • Bispecific fusion protein having therapeutic and diagnostic potential

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0065] Generation of bispecific protein / monoclonal antibody constructs for recruitment of bone marrow stem cells to vascular lesions

[0066] Materials and methods

[0067] Reagent

[0068] Biocoll separation solution was purchased from Biochrom AG (Berlin, Germany) and EBM was a "BulletKit" (EGM) from Cambrex Bio Science (East Rutherford, New Jersey). Collagen I, collagen III, laminin, vitronectin, fibrinogen, and fibronectin were purchased from BD Sciences (Heidelberg, Germany), human VEGF was purchased from PeproTech Inc. (Rocky Hill, N.J.), primary antibodies - vWF murine antibody and phalloidin - AlexaFluor 488 were purchased from Chemicon (Temecula, CA). DAPI, Cy3-labeled secondary antibody (goat anti-mouse) and "Celltracker Vybrand DiD" were purchased from MolecularProbes / Invitrogen GmbH (Karlsruhe, Germany).

[0069] Isolation and culture of CD34+ cells and CD133+ cells

[0070] Human CD34+ cells and CD133+ cells were obtained from human umbilical cord blood as des...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a bispecific construct comprising a first polypeptide that binds to collagen and a second polypeptide which binds to endothelial precursor cells. The invention further relatesto the use of said fusion protein for producing a pharmaceutical composition used for treating vascular and / or tissue lesions.

Description

technical field [0001] The present invention relates to a bispecific fusion protein with therapeutic and diagnostic potential, which is used for the treatment / diagnosis of blood vessel or tissue damage; the present invention further relates to nucleotide molecules encoding this fusion protein, including fusion proteins or nucleotides Molecular pharmaceutical and diagnostic components, use of fusion protein or nucleotide molecules in the preparation of pharmaceutical components for the treatment of blood vessel / tissue damage and a method of treating acute or chronic vascular diseases. Background technique [0002] In particular, grafting of stents or stent-grafts into blood vessels can result in damage to blood vessels in the cardiovascular system. Stents or stent-grafts must accordingly be inserted into blood vessels affected by other disorders or conditions in order to ensure the supply of peripheral tissues or organs. [0003] In the physiological state, blood circulates ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61P9/00
CPCA61K47/48561C07K16/2896A61K47/48415C07K14/705C07K2319/33A61K47/6811A61K47/6849A61P19/08A61P9/00A61P9/10A61P9/14
Inventor 哈拉尔·兰格迈因拉德·加瓦兹汉斯·尤格·比林托马斯·斯库特拉刚德拉姆·云格
Owner UNIV TUBINGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com